Viva Biotech Holdings released its monthly return for the period ended 31 August 2026, confirming that the company’s capital structure remained unchanged throughout the month.

Authorised Capital • Authorised share capital held steady at 4.00 billion ordinary shares with a par value of USD 0.000025 each, equivalent to USD 0.10 million.

Issued Shares and Public Float • Issued share count (excluding treasury shares) closed the month at 2.09 billion, identical to the prior month’s level. • No treasury shares were held or cancelled, leaving total issued shares unchanged at 2.09 billion. • The company affirmed compliance with Hong Kong’s minimum public-float requirement of 25 percent for the class of shares listed.

Share-Based Incentives • Outstanding options under the Pre-IPO Share Incentive Schemes totalled 2.22 million. • Outstanding options under the Post-IPO Share Option Scheme stood at 8.32 million, with an additional 129.73 million shares still available for future grants. • No options were granted, exercised, cancelled or lapsed during August, and no new shares were issued through option exercises. Consequently, no funds were raised via share-based transactions.

Other Equity Instruments • The company reported no warrants, convertible securities, or other agreements that could dilute equity, and no other movements in issued or treasury shares occurred during the month.

Compliance Confirmation • Management certified that all regulatory obligations under Hong Kong Listing Rules were satisfied, including the receipt of all monies due, fulfilment of listing pre-conditions, and statutory filings.

Overall, the August 2026 filing highlights a period of capital stability for Viva Biotech, with consistent share counts, adequate public float, and unchanged option positions.